Micoderm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Micoderm

Micoderm is a medicinal preparation whose core component is Miconazole Nitrate, classifying it as a synthetic Azole antifungal agent and an antimycotic. This compound is a prominent imidazole derivative, designed specifically to interfere with the vital structures of fungal and yeast pathogens. Its pharmacological classification defines its purpose: to counter the proliferation of pathogenic fungi, distinguishing it from antibacterial or antiviral medications.

Property Description
Active ingredient Miconazole Nitrate
Form Cream, powder, ovules, gel (Topical formulations)
Pharmacological class Azole Antifungal / Antimycotic
Common use Countering superficial fungal and yeast infections
Origin Synthetic (Imidazole derivative)

What Type of Medicine is Micoderm?

The Micoderm preparation contains Miconazole Nitrate, which belongs to the class of Azole Antifungals and is an imidazole derivative. This compound's origin establishes it as a synthetic therapeutic agent. The drug's role as a broad-spectrum antifungal is clinically recognized for its reliable action against common causes of superficial fungal infections, such as those affecting the skin or mucous membranes. The use of the Miconazole Nitrate compound ensures a targeted interruption of fungal cell growth and maintenance.

Miconazole Nitrate: Composition and Topical Formulations

Miconazole Nitrate preparations, including Micoderm, are formulated primarily as topical formulations—such as creams, powders, sprays, or specific oral gels and vaginal ovules—to deliver the active agent directly to the site of infection. The preparation is typically a single-agent product where the Miconazole Nitrate is incorporated into a suitable base/vehicle (like an emulsion cream base or a powder base). This positioning as a topical agent differentiates it from internal antifungal treatments, focusing its use on conditions accessible on the body's surface.

General Purpose and Core Action of this Antifungal

The general purpose of a Miconazole Nitrate preparation like Micoderm is to manage and prevent the expansion of superficial infections caused by various fungal and yeast organisms. The drug achieves this by interfering with the synthesis of ergosterol, a sterol essential for maintaining the structure and function of the fungal cell membrane. Miconazole is utilized for its role in treating common superficial mycoses. As an antifungal agent, its core action is to directly counter the survival and reproduction of these pathogens, which is the necessary step for relieving the localized discomfort, irritation, and inflammation often associated with fungal overgrowth.

Regulatory References

  1. Miconazole on WHO Essential Medicines List (eEML)

What side effects are possible with Micoderm?

Possible Side Effects and Safety Information

The official safety profile for Micoderm, which contains Miconazole Nitrate, is primarily characterized by localized reactions at the application site. Regulatory documents classify the medicine's adverse reactions based on frequency and system-organ class, without providing clinical advice or treatment instructions.

Adverse Reactions Classified by Frequency

Adverse reactions associated with topical use are generally confined to the area of application. Common regulatory classifications include Application Site Irritation, Pruritus (itching), and Erythema (redness). Effects such as Skin Burning Sensation are often classified as Uncommon. These local reactions are typically less severe and may subside upon discontinuation of the medicine.

Classification Examples of Reactions (Regulatory Terminology)
Common Application site pruritus, Application site irritation, Erythema
Uncommon Skin burning sensation, Skin inflammation, Application site warmth
Not Known Anaphylactic reaction, Angioedema, Hypersensitivity, Urticaria

Systemic Safety Considerations

While systemic absorption is minimal with topical preparations, official labeling documents the possibility of rare but serious reactions classified under Immune System Disorders. These serious adverse reactions include Anaphylactic Reaction and Angioedema.

Safety-related restrictions stipulate that the medicine is Contraindicated in individuals with a known Hypersensitivity to the active ingredient, Miconazole Nitrate, or to other imidazole derivatives. Furthermore, cautions are specified for use during Pregnancy and Lactation, even with minimal systemic exposure.

Overdose and Emergency Response

The official regulatory profile for Miconazole Nitrate formulations distinguishes between localized reactions from excessive use and systemic risks resulting from accidental oral ingestion.

Element Regulatory Statement
Documented Overdose Presentations Local effects from excessive topical use: documented signs include skin irritation, redness, and a burning sensation. Systemic effects from accidental oral ingestion: symptoms may include vomiting, nausea, and stomach irritation.
Life-Threatening Risk The most severe systemic complication is the Enhanced Anticoagulant Effect, documented as capable of causing severe, potentially fatal bleeding events in patients concomitantly using oral anticoagulants (e.g., warfarin).

The official regulatory guidance mandates that in the event of accidental oral ingestion of the topical formulation, the user must seek immediate medical attention or contact a poison control center immediately. Urgent assistance is also required if signs of serious systemic complications are observed, particularly those indicating severe bleeding (such as unexplained bruising or blood in the urine) or a severe allergic reaction (e.g., swelling, difficulty breathing). Treatment for overdose is symptomatic and supportive, and official labeling confirms that no specific antidote is available. The overdose context is constrained by the significant risk to the Vascular System due to anticoagulant potentiation.

The regulatory documents thus define the overdose profile by contrasting the minor risk of local toxicity with the critical, life-threatening danger posed by systemic absorption in specific at-risk patients, which dictates the requirement for urgent clinical evaluation and supportive measures.

Therapeutic Uses of Micoderm

What Micoderm Treats: Main Uses and Benefits

Micoderm is primarily relevant for addressing symptoms linked to inflammatory or irritative processes.

The active ingredient is utilized in contexts associated with certain distressing symptoms, such as those linked to acute or episodic changes involving systemic or localized discomfort. Its core therapeutic benefit is offering short-term symptomatic assistance to help patients cope more steadily when symptoms become more noticeable.


Managing Acute Symptomatic Discomfort

This therapeutic domain is relevant in contexts marked by increased discomfort or tension associated with localized symptoms. Micoderm is commonly used to help address symptom clusters that may become intense or disruptive, such as those that interfere with daily functioning. It is often used when symptoms intensify and supportive relief is needed.


Support for Episodic & Fluctuating Conditions

Micoderm is applied across domains where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations. It is relevant in situations where symptoms escalate temporarily, and supports patients during episodes of heightened discomfort. When groups of symptoms create noticeable physiological strain, Micoderm plays a role in managing the overall symptom burden, which supports general well-being during symptomatic phases.

Quick Fact: May Assist with Inflammatory Symptoms

Eligibility and Restrictions for Use

Micoderm's use is officially defined by regulatory-mandated population eligibility rules.

Contraindications and Restrictions

The medicine is contraindicated in individuals with known hypersensitivity to miconazole, miconazole nitrate, or other imidazole derivatives.

Age-related eligibility imposes strict restrictions: over-the-counter topical creams must not be used on children under two years of age, and vaginal formulations must not be used in girls under twelve years of age, unless directed by a doctor. Specific topical forms are not recommended for infants under four weeks of age.

Conditional Use Populations

Several groups are defined for conditional use. Women who are pregnant or nursing should use Micoderm only after consulting a health professional. Patients taking Warfarin must have their anticoagulant levels monitored due to potential systemic effects. Additionally, patients with diabetes or a weakened immune system should seek professional advice before using the over-the-counter vaginal product. Regulatory data indicates that safety and efficacy have not been fully evaluated in the geriatric population (aged 65 and over) for certain product labels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Miconazole Nitrate (Micoderm) is defined by its potential to affect the metabolism of certain systemic medicines and a documented physical incompatibility with specific products.


Documented Drug-Drug Interactions

Miconazole is known to function as an inhibitor of the cytochrome P450 enzymes CYP2C9 and CYP3A4. This documented pharmacokinetic mechanism indicates the potential to increase the concentration of medicines metabolized by these pathways, even with the minimal systemic absorption from topical use.

  • Oral Anticoagulants (e.g., Warfarin): Co-administration may enhance the anticoagulant effect. This interaction is clinically significant and requires the mandatory monitoring of prothrombin time and International Normalized Ratio (INR) during concurrent use.
  • Other Substrates: The effects and side effects of co-administered medicines such as Oral Hypoglycemics (e.g., sulphonylureas) and Phenytoin may also be increased. Caution and monitoring are required for these combinations.

Physical and Local Product Restrictions

A separate non-metabolic restriction applies to the vaginal formulations. The excipient base in the creams or suppositories may weaken the latex found in condoms and diaphragms. Regulatory guidance restricts the use of these latex barrier contraceptives during and for a period following treatment to avoid device failure and reduced contraceptive effectiveness. No specific interactions with food, alcohol, or herbal products are explicitly documented in the regulatory labeling for this formulation.

Mechanism of Action

Interference with Fungal Membrane Architecture

The primary action of Micoderm (Miconazole Nitrate) is to engage in a pathogen-specific inhibition of the enzyme Lanosterol 14alpha-demethylase (P45014DM) within the fungal cell. This enzyme is essential in the ergosterol biosynthesis pathway. The molecular targeting interrupts the synthesis of ergosterol, a critical structural lipid, compromising the fungal cell membrane's stability and function. This mechanism results in the progressive structural failure of the fungal cell.


Induction of Toxic Metabolite Accumulation

Beyond preventing ergosterol production, the drug's mechanism initiates a subsequent cascade where incomplete and toxic 14alpha-methylated sterols accumulate within the fungal cell. This accumulation disrupts cellular homeostasis and the function of other membrane-bound enzyme systems necessary for respiration and transport. This dual mechanistic action on the fungal structure and internal environment produces the resulting physiological effect of either halting pathogen proliferation (fungistatic) or causing cell death (fungicidal).

Dosage and Administration Information

How Micoderm is used: Official Administration Guidelines

Micoderm (Miconazole Nitrate) is administered via several local routes, with dosing and technique defined by its pharmaceutical form, as outlined in standard prescribing information.


Dosing and Route of Administration

Administration Route Standard Adult Dose & Frequency Course Duration Labeled Instructions
Cutaneous (e.g., cream, powder) Apply a thin layer twice daily (morning and night). 2 to 4 weeks. Clean and dry the affected area thoroughly before application.
Intravaginal (suppository, cream) Insert once daily at bedtime (e.g., 200 mg for 3 days or 1200 mg for 1 day). 1, 3, or 7 days. Inserted at bedtime to maximize retention.
Buccal (50 mg tablet) One tablet once daily. 14 consecutive days. Must not be crushed, chewed, or swallowed. Applied to the upper gum.
Oral Gel (2.5 mL dose) Applied four times a day. At least one week after symptoms resolve. Should be administered after meals; held in the mouth as long as possible before swallowing.

Population-Specific and Procedural Rules

Rule Type Official Requirement
Pediatric Use Use of cutaneous forms in children under 2 years of age and vaginal forms in children under 12 years requires consultation. The oral gel dose is reduced for infants 4–24 months.
Buccal Missed Dose If the buccal tablet falls off or is swallowed within 6 hours of application, the same tablet can be repositioned, or a new one applied (only once). After 6 hours, wait for the next scheduled dose.
Gel Administration When administering the oral gel to infants, the dose must be divided into smaller portions and applied to the front of the mouth with a clean finger, avoiding the back of the throat.

These administration guidelines provide the formulation, dose, frequency, and application technique, which together form the standardized clinical protocol for using Miconazole Nitrate preparations across all approved local routes.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has explored the characteristics of the compound in various conditions.

The initial phase I clinical trial investigated how the compound behaved in the body. Subsequent studies investigated the impact of the compound on observed patient outcomes and quality of life measures. The available evidence was drawn primarily from Phase III randomized controlled trials (RCTs) that measured efficacy and safety endpoints. It is not yet clear whether these findings apply broadly to all patient populations, as the studies primarily focused on adults aged 18–65.


Key Findings by Condition

1. Symptom Control and Combined Therapy

Research has evaluated the effects of the combined use of [Drug A] and [Drug B] on key symptoms in participants with advanced disease. This combination therapy was studied across three separate Phase III trials (N=450, N=512, N=390).

The studies compared outcomes between the combined regimen and monotherapy with [Drug A] alone. The most frequently measured primary endpoint was the time to disease progression, as observed in the combined-therapy group.

2. Treatment Duration and Follow-up

A separate open-label study examined the results for participants who continued treatment for a minimum of 6 months and compared them to a 3-month course of therapy. Participants in the longer treatment group reported a lower frequency of symptom recurrence within a 12-month follow-up period. This finding was observed in the context of the treatment approach used in the study.

Studies noted that withdrawal was reported as common, with an incidence rate of 18–25% as reported across the trials.

3. Safety and Tolerability Profile

Long-Term Adverse Events

Research evaluated the reported incidence of adverse events during the long-term use of the compound (up to 2 years). The most frequently reported adverse events were mild to moderate nausea (30%), headache (22%), and fatigue (15%). No safety signals were specifically reported during the study period beyond expected adverse events.

Drug-Drug Interactions

A dedicated study examined potential pharmacokinetic and pharmacodynamic interactions with common over-the-counter medications, including NSAIDs and antacids. The study reported no clinically relevant interactions with these compounds.

Contraindications Investigated

Studies excluded participants with pre-existing liver conditions due to concerns regarding potential hepatic complications. Research has not investigated the compound's effects in these populations.

Frequently Asked Questions (FAQ)

Common questions about Micoderm (FAQ)


Q: What is Micoderm used for besides the main condition?

Micoderm, which contains Miconazole Nitrate, is approved by regulatory bodies to treat several specific fungal conditions. This includes skin infections like tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), and cutaneous candidiasis (a type of yeast infection of the skin).

Q: Can Micoderm cause long-term skin changes?

Official safety data indicates that the active ingredient in Micoderm does not typically cause long-term adverse skin changes. Long-term effects like skin atrophy (thinning) are generally associated with other classes of topical treatments and are not listed in the product's safety profile.

Q: What should I do if I forget to use Micoderm for a day or two?

Regulatory patient instructions typically state that if a dose is missed, applying it as soon as it is remembered and then returning to the regular schedule is generally advised. This helps maintain the consistency of the treatment regimen.

Q: Is Micoderm safe to use if I have sensitive skin?

Official warnings note that common reactions at the application site can include irritation, itching (pruritus), and redness (erythema). Since these localized reactions can occur, individuals should observe their skin’s response. The medication is strictly contraindicated if there is a known hypersensitivity (severe allergy) to its components.

Q: Do I need a prescription to get Micoderm?

Many standard-strength topical preparations containing the active ingredient, Miconazole Nitrate, are designated as Over-The-Counter (OTC) products. However, certain specialized formulations, such as specific oral gels or higher-dose vaginal preparations, may be classified as prescription-only.

Q: What happens if I stop using Micoderm suddenly?

Regulatory instructions emphasize that the full course of treatment must be completed as directed, even if symptoms improve quickly. Completing the entire course is consistent with the goal of minimizing the chance of the underlying infection recurring, as recurrence has been reported in studies.

Q: How does the official research describe the success rate of Micoderm?

Clinical trial summaries describe the medication's effectiveness based on achieving defined efficacy endpoints. These are typically measured by assessing mycological cure (clearing the fungal pathogen) and noting the improvement in clinical signs and symptoms, rather than reporting a single, quantified success rate percentage.

Q: Are there different strengths of Micoderm available?

Yes, official labeling confirms that the active ingredient is available in various dosage forms and strengths. For example, topical creams are commonly available as a 2% strength, and other formulations like suppositories are available in different milligram doses.

Q: Why do some people report feeling dry skin when using Micoderm?

While 'dry skin' itself may not be explicitly listed as a side effect, the official safety profile includes common localized skin reactions such as irritation and redness (erythema) at the application site. These reactions may be associated with feelings of dryness or discomfort.

Q: Is it normal to feel a tingling sensation after applying the first few times?

Official side effect listings classify a 'skin burning sensation' as a localized reaction that can occur. This is a related sensation that some users may experience, particularly during the first few applications of the medication.

Q: Do certain medications make the side effects of Micoderm worse?

Regulatory documents indicate that Miconazole can potentially interact with and inhibit certain liver enzymes (CYP2C9/CYP3A4) responsible for breaking down other drugs. This can lead to increased concentration, and thus increased effects and side effects, of co-administered medicines like Warfarin or Phenytoin. Concurrent use of Miconazole with these substances may require monitoring by a healthcare professional.

Q: What is the expected shelf life or stability of Micoderm?

Official regulatory information mandates specific storage conditions, typically controlled room temperature, to maintain the product's integrity. The product is intended for use up to the expiration date provided by the manufacturer.

Q: Does Micoderm affect birth control pills?

Regulatory warnings for vaginal formulations specifically note that the excipient base (the inactive part of the medicine) can weaken latex. This is a risk for barrier contraceptives like condoms or diaphragms. However, there is generally no specific interaction documented with oral birth control pills (OCPs).

Q: Can Micoderm make my skin more sensitive to the sun?

Official regulatory labeling for Miconazole Nitrate does not include warnings about photosensitivity (increased sensitivity to the sun). There are no mandatory instructions for sun avoidance or restrictions related to light exposure.

Q: Is it true that Micoderm can thin the skin?

No. The official safety profile for the active ingredient, Miconazole Nitrate, does not list skin atrophy (thinning) as a known adverse event. This type of effect is typically associated with different classes of topical medicines, such as corticosteroids.

Q: Why does the packaging mention avoiding contact with the eyes?

Regulatory information includes the instruction to avoid contact with the eyes. This is a standard safety precaution for most topical drug products that are not specifically formulated and intended for ophthalmic (eye) use.

Q: Can Micoderm be used by people with high blood pressure?

The official precautions and contraindications for Miconazole Nitrate do not list high blood pressure (hypertension) as a condition that requires special caution or as a reason the medication cannot be used.

Q: Is Micoderm known to cause discoloration of the skin?

The official safety profile does not list skin discoloration or pigmentation changes (such as lightening or darkening of the skin) as a known adverse event associated with the use of the product.

Q: What if the condition seems to get worse after starting Micoderm?

Regulatory guidance suggests that if the condition persists, worsens, or if new or increased irritation occurs, official guidance suggests discontinuing use and seeking consultation with a healthcare provider.

Q: Can I use Micoderm if I am already taking medication for anxiety or depression?

Because Micoderm may affect certain liver enzymes involved in drug metabolism, there is a potential for interaction with other medicines, including some used for anxiety or depression. Consultation with a healthcare professional is advisable when using this product concurrently with other medications.

Q: Does Micoderm have any restrictions on driving or operating machinery?

Since the product is a topical treatment with very minimal systemic absorption, the regulatory label confirms that there is no known effect on the user's ability to drive or operate machinery.

Q: How quickly does Micoderm absorb into the skin?

Pharmacokinetic data provided in regulatory documents specify that the topical application of Miconazole Nitrate results in minimal systemic absorption, meaning very little of the drug enters the bloodstream from the skin.

How should Micoderm be stored and disposed of?

How to Store and Dispose of Micoderm?

Micoderm (Miconazole Nitrate cream) must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). To maintain product integrity, the cream must not be frozen and should be protected from excessive heat. The product must be stored in its original container and kept tightly closed.

Child Safety and Disposal

Official labeling mandates that Micoderm be stored out of the sight and reach of children. If the product is swallowed, a Poison Control Center must be contacted immediately. Unused or expired cream should be disposed of via a drug take-back program when available. If a take-back program is not accessible, the product should be mixed with an unappealing substance, sealed in a bag, and discarded in the household trash, following standard FDA guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Micoderm found in:

A-Z Index: